News

News
17 January 2022

GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition

Since December 2019, SARS-CoV-2 has spread quickly worldwide, leading to more than 280 million confirmed…
Read More
News
17 December 2021

GENOSCIENCE PHARMA out licenses rights of GNS561 in Europe, US and Canada territories in Cholangiocarcinoma

Genoscience is proud to announce the out-licensing of GNS561 in the cholangiocarcinoma in the United…
Read More
News
8 November 2021

GNS561, a clinical-stage PPT1 inhibitor is efficient against Hepatocarcinoma via modulation of lysosomal functions

The Genoscience Pharma's team and its collaborators are happy of this new publication in Autophagy…
Read More
News
13 September 2021

GNS561, active against Cancer Stem Cells.

A new article has been recently published in the #journalofcancer showing that #GNS561, a new #autophagy blocker, offers great…
Read More
Events
January 11-16, 2021

Biotech Showcase™ 2021

Biotech Showcase™ 2021_ Investor Digital Conference Excited to attend the 2021 Digital Investor Conference which…
Read More
Events
November 19-20, 2020

2020 Drugging Autophagy Summit

Genoscience Pharma has presented at The Drugging Autophagy Summit its Phase 1b results, where all…
Read More
News
Nov. 18, 2020

GNS561’s successful phase 1b trial completed

Genoscience Pharma completes successful phase 1b trial evaluating GNS561, PPT-1 inhibitor, in patients with primary…
Read More
News
July 22, 2020

GNS561, a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition

Marseille, July 22, 2020_ Therapeutic Advances in Chronic disease just published Genoscience Pharma's article E…
Read More
News
18 June, 2020

Our COVID-19 research Project supported by the French Government

Marseille, June 18, 2020_ The French Government announced in today's press release that Genoscience Pharma…
Read More
Events
June 22-24, 2020

AACR 2020 Virtual Annual Meeting

GENOSCIENCE PHARMA Announces Remarkable Data on GNS561 in Combination with anti-PD1 to be Presented at…
Read More